{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T17:16:04Z","timestamp":1783617364307,"version":"3.55.0"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"27","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7,3]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      To clarify whether specific immune cell phenotypes exert a causal influence on diabetic nephropathy (DN), we conducted a Mendelian randomization (MR) investigation using large-scale genetic datasets. Summary-level data for immune cell traits and DN were obtained from recent genome-wide association studies and the FinnGen consortium. Genetic instruments were selected under the core MR assumptions, ensuring strong relevance and minimal confounding. The inverse-variance weighted approach served as the primary analytical framework. Complementary analyses, including MR-Egger regression, Cochran\n                      <jats:italic toggle=\"yes\">Q<\/jats:italic>\n                      test, and leave-one-out procedures, were performed to detect horizontal pleiotropy, assess heterogeneity, and evaluate the stability of the findings. Genetically predicted increases in several immune cell phenotypes were associated with higher genetic susceptibility to DN, including CD25 on IgD\u2212 CD38dim (odds ratio [OR]: 1.153,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.026), CD8dim AC (OR: 1.144,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.045), HLA DR on CD33br HLA DR+ CD14\u2212 (OR: 1.142,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;\u2005.001), CD39+ CD8br %CD8br (OR: 1.094,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.047), and CD25hi CD45RA+ CD4 not Treg %T cell (OR: 1.051,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.041). Conversely, higher SSC-A on CD4+ cells was associated with lower genetic susceptibility to DN (OR: 0.385,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;\u2005.001). No evidence of horizontal pleiotropy was detected (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005\u2265\u2005.05). Cochran\n                      <jats:italic toggle=\"yes\">Q<\/jats:italic>\n                      indicated no significant heterogeneity. Sensitivity analyses confirmed the robustness of all associations. This MR analysis suggests that HLA DR on CD33br HLA DR+ CD14\u2212 is associated with increased genetic susceptibility to DN, whereas SSC-A on CD4+ is associated with decreased susceptibility. These findings offer genetic evidence of immune involvement in DN susceptibility and warrant further validation and investigation to clarify mechanisms and relevance.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000049443","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T17:00:52Z","timestamp":1783098052000},"page":"e49443","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Immune cell phenotypes in the context of diabetic nephropathy: A Mendelian randomization analysis"],"prefix":"10.1097","volume":"105","author":[{"given":"Keke","family":"Tong","sequence":"first","affiliation":[{"name":"Department of Endocrinology, The First Hospital of Hunan University of Chinese Medicine, Changsha, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, The First Hospital of Hunan University of Chinese Medicine, Changsha, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunfeng","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, The First Hospital of Hunan University of Chinese Medicine, Changsha, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Xiang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, The First Hospital of Hunan University of Chinese Medicine, Changsha, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyi","family":"Wu","sequence":"additional","affiliation":[{"name":"The Third School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weili","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The Third Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9017-9183","authenticated-orcid":false,"given":"Juan","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, The First Hospital of Hunan University of Chinese Medicine, Changsha, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260709","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1053\/j.ajkd.2017.10.026","article-title":"Update on diabetic nephropathy: core curriculum 2018.","volume":"71","author":"Umanath","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"R3-20260709","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.diabres.2011.10.029","article-title":"IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030.","volume":"94","author":"Whiting","year":"2011","journal-title":"Diabetes Res Clin Pract"},{"key":"R4-20260709","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/dom.14007","article-title":"An updated overview of diabetic nephropathy: diagnosis, prognosis, treatment goals and latest guidelines.","volume":"22","author":"Selby","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"R5-20260709","doi-asserted-by":"crossref","first-page":"672350","DOI":"10.3389\/fendo.2021.672350","article-title":"Global, regional, and national burden of diabetes-related chronic kidney disease from 1990 to 2019.","volume":"12","author":"Deng","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R6-20260709","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-1-4939-9841-8_1","article-title":"Diabetic nephropathy: an overview.","volume":"2067","author":"Sagoo","year":"2020","journal-title":"Methods Mol Biol"},{"key":"R7-20260709","doi-asserted-by":"crossref","first-page":"865","DOI":"10.2337\/diabetes.48.4.865","article-title":"Is diabetic nephropathy inherited? Studies of glomerular structure in type 1 diabetic sibling pairs.","volume":"48","author":"Fioretto","year":"1999","journal-title":"Diabetes"},{"key":"R8-20260709","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.2337\/diacare.15.9.1205","article-title":"Diabetic nephropathy. Metabolic versus hemodynamic considerations.","volume":"15","author":"Hostetter","year":"1992","journal-title":"Diabetes Care"},{"key":"R9-20260709","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nrneph.2015.175","article-title":"Innate immunity in diabetes and diabetic nephropathy.","volume":"12","author":"Wada","year":"2016","journal-title":"Nat Rev Nephrol"},{"key":"R10-20260709","first-page":"1841690","article-title":"Immune cells and inflammation in diabetic nephropathy.","volume":"2016","author":"Zheng","year":"2016","journal-title":"J Diabetes Res"},{"key":"R11-20260709","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1016\/S0140-6736(00)04904-7","article-title":"An overview of the immune system.","volume":"357","author":"Parkin","year":"2001","journal-title":"Lancet"},{"key":"R12-20260709","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/s41581-019-0234-4","article-title":"Innate immunity in diabetic kidney disease.","volume":"16","author":"Tang","year":"2020","journal-title":"Nat Rev Nephrol"},{"key":"R13-20260709","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1042\/CS20160636","article-title":"Diabetic nephropathy \u2013 is this an immune disorder?","volume":"131","author":"Tesch","year":"2017","journal-title":"Clin Sci (Colch)"},{"key":"R14-20260709","first-page":"a041302","article-title":"Mendelian randomization.","volume":"12","author":"Birney","year":"2022","journal-title":"Cold Spring Harb Perspect Med"},{"key":"R15-20260709","doi-asserted-by":"crossref","first-page":"k601","DOI":"10.1136\/bmj.k601","article-title":"Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians.","volume":"362","author":"Davies","year":"2018","journal-title":"BMJ"},{"key":"R16-20260709","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1038\/s41588-020-0684-4","article-title":"Complex genetic signatures in immune cells underlie autoimmunity and inform therapy.","volume":"52","author":"Orr\u00f9","year":"2020","journal-title":"Nat Genet"},{"key":"R17-20260709","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1001\/jama.2021.18236","article-title":"Strengthening the reporting of observational studies in epidemiology using Mendelian randomization: the STROBE-MR statement.","volume":"326","author":"Skrivankova","year":"2021","journal-title":"JAMA"},{"key":"R18-20260709","doi-asserted-by":"crossref","first-page":"1018608","DOI":"10.3389\/fendo.2022.1018608","article-title":"Depiction of immune heterogeneity of peripheral blood from patients with type II diabetic nephropathy based on mass cytometry.","volume":"13","author":"Jin","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R19-20260709","first-page":"137","article-title":"Role of CD4+CD25+foxp3+ regulatory T cells in type 2 diabetic nephropathy.","volume":"29","author":"Xu","year":"2009","journal-title":"Nan Fang Yi Ke Da Xue Xue Bao"},{"key":"R20-20260709","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1749-6632.2011.06449.x","article-title":"CD33-related siglecs as potential modulators of inflammatory responses.","volume":"1253","author":"Crocker","year":"2012","journal-title":"Ann N Y Acad Sci"},{"key":"R21-20260709","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1365-2567.2010.03368.x","article-title":"Evolution of CD33-related siglecs: regulating host immune functions and escaping pathogen exploitation?","volume":"132","author":"Cao","year":"2011","journal-title":"Immunology"},{"key":"R22-20260709","doi-asserted-by":"crossref","first-page":"15091","DOI":"10.1073\/pnas.96.26.15091","article-title":"Engagement of p75\/AIRM1 or CD33 inhibits the proliferation of normal or leukemic myeloid cells.","volume":"96","author":"Vitale","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R23-20260709","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/JLB.3RU0420-668RR","article-title":"HLA-DR-expressing NK cells: effective killers suspected for antigen presentation.","volume":"109","author":"Erokhina","year":"2021","journal-title":"J Leukoc Biol"},{"key":"R24-20260709","doi-asserted-by":"crossref","first-page":"303","DOI":"10.3889\/oamjms.2018.080","article-title":"CD33+ HLA-DR\u2013 myeloid-derived suppressor cells are increased in frequency in the peripheral blood of type1 diabetes patients with predominance of CD14+ subset.","volume":"6","author":"Hassan","year":"2018","journal-title":"Open Access Maced J Med Sci"},{"key":"R25-20260709","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.2337\/db11-0358","article-title":"Potential role of regulatory T cells in reversing obesity-linked insulin resistance and diabetic nephropathy.","volume":"60","author":"Eller","year":"2011","journal-title":"Diabetes"},{"key":"R26-20260709","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1007\/s00125-010-1757-1","article-title":"Lymphocytes promote albuminuria, but not renal dysfunction or histological damage in a mouse model of diabetic renal injury.","volume":"53","author":"Lim","year":"2010","journal-title":"Diabetologia"},{"key":"R27-20260709","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/nm.1964","article-title":"CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity.","volume":"15","author":"Nishimura","year":"2009","journal-title":"Nat Med"},{"key":"R28-20260709","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/sji.12309","article-title":"Haemodialysis in diabetic patients modulates inflammatory cytokine profile and T cell activation status.","volume":"82","author":"Almeida","year":"2015","journal-title":"Scand J Immunol"},{"key":"R29-20260709","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.molmed.2013.03.005","article-title":"CD39 and CD73 in immunity and inflammation.","volume":"19","author":"Antonioli","year":"2013","journal-title":"Trends Mol Med"},{"key":"R30-20260709","doi-asserted-by":"crossref","first-page":"283","DOI":"10.5372\/1905-7415.0802.291","article-title":"High glucose enhances CD39 expression in vascular endothelial cells.","volume":"8","author":"Kongkhum","year":"2014","journal-title":"Asian Biomed"},{"key":"R31-20260709","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s11302-012-9342-3","article-title":"The CD39-adenosinergic axis in the pathogenesis of renal ischemia-reperfusion injury.","volume":"9","author":"Roberts","year":"2013","journal-title":"Purinergic Signal"},{"key":"R32-20260709","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.4049\/jimmunol.1002615","article-title":"Elevated proinflammatory cytokine production by a skewed T cell compartment requires monocytes and promotes inflammation in type 2 diabetes.","volume":"186","author":"Jagannathan-Bogdan","year":"2011","journal-title":"J Immunol"},{"key":"R33-20260709","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.trsl.2015.04.013","article-title":"Targeting T helper 17 by mycophenolate mofetil attenuates diabetic nephropathy progression.","volume":"166","author":"Kim","year":"2015","journal-title":"Transl Res"},{"key":"R34-20260709","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jaci.2009.02.011","article-title":"IL-2- and CD25-dependent immunoregulatory mechanisms in the homeostasis of T-cell subsets.","volume":"123","author":"L\u00e9tourneau","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"R35-20260709","first-page":"624","article-title":"Clinical significance of changes on serum heparanase and interleukin-2 levels in type 2 diabetic nephropathy patients.","volume":"42","author":"Gan","year":"2013","journal-title":"Chongqing Medicine"},{"key":"R36-20260709","first-page":"110","article-title":"Correlation analysis between urinary microalbumin excretion rate and free fatty acids, urinary podocyte marker protein, interleukin-2, and interleukin-8 in patients with type 2 diabetic nephropathy.","volume":"8","author":"He","year":"2023","journal-title":"Doctor"},{"key":"R37-20260709","first-page":"16","article-title":"Evaluation of helper T lymphocyte subpopulations: naive (CD4+CD45RA+), memory (CD4+CD45RO+) and co-expression of phenotypes CD45RA+ and CD45RO+ in preclinical phases of diabetes type 1 (prediabetes).","volume":"58","author":"Kretowski","year":"2001","journal-title":"Przegl Lek"},{"key":"R38-20260709","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1093\/intimm\/5.5.479","article-title":"Role of CD4+CD45RA+ T cells in the development of autoimmune diabetes in the non-obese diabetic (NOD) mouse.","volume":"5","author":"Semp\u00e9","year":"1993","journal-title":"Int Immunol"},{"key":"R39-20260709","doi-asserted-by":"crossref","first-page":"11325","DOI":"10.18632\/aging.103410","article-title":"CD38 inhibition by apigenin ameliorates mitochondrial oxidative stress through restoration of the intracellular NAD+\/NADH ratio and Sirt3 activity in renal tubular cells in diabetic rats.","volume":"12","author":"Ogura","year":"2020","journal-title":"Aging (Albany NY)"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000049443","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T17:02:46Z","timestamp":1783616566000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000049443"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":38,"journal-issue":{"issue":"27","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000049443","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,3]]},"assertion":[{"value":"2025-12-31","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-05","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}